Our sister blog, The Sample, is hard at work covering the AACC annual meeting. Kirell Lakhman has a series of posts up and from Friday's session, he writes about new molecular techs flocking to pharma and linking oxaliplatin toxicity to the glutathione S-transferase gene. Yesterday, Lakhman blogged about what molecular diagnostic labs should keep in mind when trying to quantify serum tumor markers using LC-MS/MS and how revamping the US health care system may affect clinical labs. Lakhman is also noting interesting quotes he's heard, such as the University of Washington's Andrew Hoofnagle saying the software bundle to a mass spec "can be testy at times." If you've heard anything good, let him know.
The Low-Down on AACC
Jul 22, 2009